Anonymous
Guest
Anonymous
Guest
And how would we know that?
Because intelligent, motivated people stay in constant contact with those they would like to receive an offer from. Don't be so lazy and expect everything to come to you!
And how would we know that?
I have been in contact with my Quintiles manager, who failed to mention the launch meetings. We were told not to contact the J and J managers until offers have been made, so excuse me for being "lazy".
The field sales reps are in the launch meeting. The people who are extending the offers are not at the meeting. This logic is not.Does anyone not realize that for the last few days they have been in meetings launching Nucynta ER? Thats why there has been delay. Expect offers to go out next week after Labor Day
The field sales reps are in the launch meeting. The people who are extending the offers are not at the meeting. This logic is not.
The delay has to do with Xarelto Afib and what JNJ really needs.
Youre an idiot...the managers are in the meetings as well obviously.
As far as the AF indication its not coming until November so youre telling me they are waiting on that? Not true. Not to mention the launch for that indication is going to be first week in November in San Diego, with that being said they need their reps (contract or not) trained on Nucynta and Xeralto with current indications before the AF indication comes.
So my friend, YOUR logic makes SOME sense
Janssen managers are not the same people making the decision about when to extend Quintiles offers. Nor are they the ones to contact interviewees. It has been out of their hands since they signed-off on who they want and don't want.
Next week, FDA is meeting about if Xarelto (not Xeralto) should get Afib. GOOGLE: Xarelto rebound effect. Internal j&j soft launch in San D means nothing.
Janssen managers are not the same people making the decision about when to extend Quintiles offers. Nor are they the ones to contact interviewees. It has been out of their hands since they signed-off on who they want and don't want. Next week, FDA is meeting about if Xarelto (not Xeralto) should get Afib. GOOGLE: Xarelto rebound effect. Internal j&j soft launch in San D means nothing.
Heard from a couple of good sources that 6517 might be delayed or cancelled due to lack of approvals. Anyone else hear this?
last i heard, they want to have hiring letters signed by labor day. that means you should hear something by friday at the latest. It wouldn't make sense it would be delayed because they are beefing up for a product that was recently launched. If anyone else knows something i don't know please respond...i am sitting on an offer thru publicis i don't want to accept!
The latest I heard was that all written offers will be delivered this week. Contract start date is September 19 or September 26, based on the area. Does anyone feel as if this contract is in jeopardy?